Latest Safety News

Page 11 of 252
K&S Corporation’s FY2026 annual report confirms a sharp earnings decline, a lower dividend and rising debt as weak demand, margin pressure and the loss of most InfraBuild work weigh on the logistics group. Management expects FY2027 to remain difficult, with no formal earnings guidance provided.
Victor Sage
Victor Sage
19 Oct 2026
Actinogen Medical says its pivotal XanaMIA Alzheimer’s trial remains on course for topline results in November after the final patient visit was completed. The company also reported $15.9 million in cash, a further $5.3 million from option funding and a projected runway into late 2027 or 2028, assuming future trials are substantially partner-funded.
Ada Torres
Ada Torres
19 Oct 2026
Acrux has received clearer FDA guidance for Phase III trials of its female testosterone spray, including potential three-year data exclusivity if the product reaches submission. The company also reported positive September-quarter operating cash flow, but that result was largely driven by a $1.977 million R&D tax rebate and Acrux says it is still pursuing funding for the clinical programme.
Victor Sage
Victor Sage
19 Oct 2026
Nyrada has moved its PROTECT-MI heart-attack trial into active recruitment, with four hospitals open and three patients dosed. The biotech also reported supportive US FDA feedback, encouraging preclinical oncology data and AU$13.72 million in cash after a AU$12 million placement.
Ada Torres
Ada Torres
19 Oct 2026
AdAlta expects an additional R&D Tax Incentive refund of more than A$1 million after securing approval for specified overseas work on its EW-001 CAR-T therapy. The cash benefit arrives as the company prepares for a US FDA pre-IND meeting in November.
Ada Torres
Ada Torres
19 Oct 2026
Advanced Braking Technology increased Q1 FY27 product sales by 8.3% and ended September with $7.3 million in bank cash. The mining safety company also moved BRAKEiQ closer to CAS Level 9 certification, although the quarter produced a small loss before tax.
Victor Sage
Victor Sage
19 Oct 2026
Aeris Resources finished FY26 with $178.5 million in net profit, $290.2 million of EBITDA and no material debt, while Tritton’s copper reserves expanded sharply. The challenge now shifts from rebuilding the balance sheet to converting a larger resource base into sustained production.
Maxwell Dee
Maxwell Dee
16 Oct 2026
Noxopharm has completed its first-in-human safety trial for SOF-SKN and advanced the wider Sofra platform, but its annual report flags a material uncertainty over funding. The biotech ended June with A$293,573 in cash, net liabilities of A$3.65 million and a need for additional capital.
Ada Torres
Ada Torres
16 Oct 2026
Gulf Stream Energy has identified oil in two separate sandstone zones at its Zydeco project in Louisiana, although the result is based solely on wireline logs and has not yet been flow-tested. The well also retains access to the undrilled Upper Tweedle gas and condensate target.
Victor Sage
Victor Sage
16 Oct 2026
Latrobe Magnesium says its Phase 1B demonstration plant is 95% installed and 35% commissioned, keeping first magnesium metal crowns above 98% purity on track for the end of 2026. The operational advance comes alongside a tight funding position, an extended A$3.4 million entitlement offer and an ambitious South Carolina expansion plan.
Victor Sage
Victor Sage
16 Oct 2026
Deep Yellow has withdrawn its target for a fourth-quarter 2026 Final Investment Decision on the Tumas uranium project, citing weak equity market conditions and constrained funding options. Construction continues, but the company has not provided a revised FID date or funding structure.
Maxwell Dee
Maxwell Dee
16 Oct 2026
Bass Oil’s September revenue surged to A$1.69 million as Bunian 6 drove a sharp increase in Indonesian production and Cooper Basin sales resumed. The company is now targeting first gas from Vanessa by year end, subject to regulatory approval and remaining site work.
Victor Sage
Victor Sage
15 Oct 2026

Browse the archive

Full archive